Physician profile
Ece Turhal
NPI 1245711001
$2,731.17
in general payments reported to CMS, 2019-2025
14 companies · $23.65 in 2025
The $23.65 reported for 2025 was less than what a typical Optometrist provider received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $712 · 2020: $829 · 2021: $634 · 2022: $126 · 2023: $304 · 2024: $102 · 2025: $23.65.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $412 · Entertainment: $17.35.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $412.03 |
| Entertainment | $17.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Johnson & Johnson Vision Care, INC. | $651.93 | 2019-2023 | Acuvue |
| Alcon Vision LLC | $633.85 | 2019-2021 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $426.86 | 2019-2021 | |
| Coopervision INC. | $410.85 | 2019-2025 | Myday Contact Lens, Paragon Crt |
| Visioneering Technologies, INC. | $151.05 | 2019-2021 | |
| Abbvie INC. | $126.28 | 2022 | |
| Carl Zeiss Meditec, INC. | $75.36 | 2024 | |
| Allergan, INC. | $67.78 | 2021 | |
| Optos, INC. | $62.09 | 2019-2023 | Panoramic Ophthalmoscope, Oct Ophthalmoscope, Nfc-700 |
| Johnson & Johnson Surgical Vision, INC. | $44.60 | 2020 | |
| Horizon Therapeutics Plc | $23.58 | 2023 | Tepezza |
| Kala Pharmaceuticals, INC. | $21.76 | 2021 | |
| Carl Zeiss Meditec Ag | $19.40 | 2020 | |
| Sun Pharmaceutical Industries INC. | $15.78 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ece Turhal listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.